Novo Nordisk has announced new data showing that its once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist Ozempic provided greater weight reductions than Eli Lilly’s rival drug Trulicity in adults with type II diabetes. More: Novo’s Ozempic beats Lilly’s Trulicity on
read moreRegenerative medical devices group Tissue Regenix has been granted a Human Tissue Authority (HTA) licence to import and distribute its portfolio of human tissue derived products from the US for use in the UK market. More: Tissue Regenix secures HTA
read moreCentral and North West London NHS Foundation Trust is intending to launch the first center that aims to treat internet addiction. More: NHS Trust plans first internet addiction centre Source: News
read moreHealth secretary Jeremy Hunt has unveiled new plans to halve the number of obese children by 2030. More: Government unveils new plans to tackle childhood obesity Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals